» Authors » Tomomi Oshima

Tomomi Oshima

Explore the profile of Tomomi Oshima including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 48
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Shimada Y, Izumi Y, Yasuoka Y, Oshima T, Nagaba Y, Nanami M, et al.
Int J Mol Sci . 2024 Sep; 25(17). PMID: 39273415
Many large-scale studies revealed that exogenous erythropoietin, erythropoiesis-stimulating agents, have no renoprotective effects. We reported the renoprotective effects of endogenous erythropoietin production on renal function in ischemic reperfusion injury (IRI)...
2.
Shinohara R, Oshima T, Otsubo T, Ariga K, Ono T, Muneoka K, et al.
Neuropsychopharmacol Rep . 2024 Jul; 44(3):599-603. PMID: 38961521
Background: In patients with schizophrenia, violent behavior is a clinically important factor that prevents their discharge. Clozapine is an effective antipsychotic medication for treatment-resistant schizophrenia, and its usefulness for aggressive...
3.
Yasuoka Y, Izumi Y, Fukuyama T, Oshima T, Yamazaki T, Uematsu T, et al.
Int J Mol Sci . 2024 Jan; 25(2). PMID: 38279224
Many large-scale studies show that exogenous erythropoietin, erythropoiesis-stimulating agents, lack any renoprotective effects. We investigated the effects of endogenous erythropoietin on renal function in kidney ischemic reperfusion injury (IRI) using...
4.
Hatakeyama H, Oshima T, Ono S, Morimoto Y, Takahashi N
Front Physiol . 2023 Dec; 14:1287275. PMID: 38124716
Mobilization of intracellular insulin granules to the plasma membrane plays a crucial role in regulating insulin secretion. However, the regulatory mechanisms of this mobilization process have been poorly understood due...
5.
Yasuoka Y, Izumi Y, Fukuyama T, Omiya H, Pham T, Inoue H, et al.
Molecules . 2022 Feb; 27(3). PMID: 35164384
Anemia is a major complication of chronic renal failure. To treat this anemia, prolylhydroxylase domain enzyme (PHD) inhibitors as well as erythropoiesis-stimulating agents (ESAs) have been used. Although PHD inhibitors...
6.
Yasuoka Y, Izumi Y, Fukuyama T, Inoue H, Oshima T, Yamazaki T, et al.
Molecules . 2021 Sep; 26(17). PMID: 34500833
The kidney is a main site of erythropoietin production in the body. We developed a new method for the detection of Epo protein by deglycosylation-coupled Western blotting. Detection of deglycosylated...
7.
Yasuoka Y, Fukuyama T, Izumi Y, Yamashita T, Nakayama Y, Inoue H, et al.
Heliyon . 2020 Nov; 6(11):e05389. PMID: 33195841
Doping tests for the illegal use of erythropoiesis-stimulating agents (ESAs) have been developed. We developed a new Western blotting method to detect and distinguish endogenous erythropoietin (Epo, 35-38 kDa) and...
8.
Yasuoka Y, Fukuyama T, Izumi Y, Nakayama Y, Inoue H, Yanagita K, et al.
Physiol Rep . 2020 Jun; 8(12):e14485. PMID: 32592328
The detection of erythropoietin (Epo) protein by Western blotting has required pre-purification of the sample. We developed a new Western blot method to detect plasma and urinary Epo using deglycosylation....
9.
Yasuoka Y, Izumi Y, Nagai T, Fukuyama T, Nakayama Y, Inoue H, et al.
Biochem Biophys Res Commun . 2018 Aug; 503(4):3121-3127. PMID: 30146260
Erythropoietin has been thought to be secreted to plasma soon after the production because of the difficulty of Western blot analysis and immunohistochemistry. We established the new methods of Western...
10.
Haramoto Y, Takahashi S, Oshima T, Onuma Y, Ito Y, Asashima M
Sci Rep . 2015 Jun; 5:11603. PMID: 26112133
Insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) signalling is required for normal embryonic growth and development. Previous reports indicated that the IGF/IGF1R/MAPK pathway contributes to neural induction and...